Inter-University Attraction Poles Phase VII P7/16 Network: An integrated approach towards understanding the pathogenesis of neurodegeneration





Home IAP NEUROBRAINNET network Project Scientific Publications Reports & Activities

IAP VII P7/16 Publications

P3. Peter Paul De Deyn


→2016   →2015   →2014   →2013   →2012   

2016 →top

Hubin E, Vanschoenwinkel B, Broersen K, De Deyn PP, Koedam N, van Nuland NA, Pauwels K (2016) Could ecosystem management provide a new framework for Alzheimer's disease? Alzheimers Dement 12(1): 65-74.e1 () pdf(private)

Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IH, Tsolaki M, Skarsgård C, Åstrand R, Wallin A, Vyhnalek M, Holmber-Clausen M, Forlenza OV, Ghezzi L, Ingelsson M, Hoff EI, Roks G, de Mendonça A, Papma JM, Izagirre A, Taga M, Struyfs H, Alcolea DA, Frölich L, Balasa M, Minthon L, Twisk JW, Persson S, Zetterberg H, van der Flier WM, Teunissen CE, Scheltens P, Blennow K (2016) Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12(2): 154-63 () pdf(private)

Janssen L, Keppens C, De Deyn PP, Van Dam D (2016) Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. Biochim Biophys Acta 1862(1): 105-12 () pdf(private)

Wostyn P, De Groot V, Van Dam D, Audenaert K, Killer HE, De Deyn PP (2016) Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension. Clin Exp Optom 99(3): 213-8 () pdf(private)

De Roeck E, Ponjaert-Kristoffersen I, Bosmans M, De Deyn PP, Engelborghs S, Dierckx E (2016) Are depressive symptoms in mild cognitive impairment predictive of conversion to dementia? Int Psychogeriatr 28(6): 921-8 () pdf(private)

Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, De Deyn PP, Vanderstichele H, Engelborghs S (2016) Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. J Alzheimers Dis 51(1): 97-106 () pdf(private)

Van Dam D, Vermeiren Y, Dekker AD, Naudé PJ, De Deyn PP (2016) Neuropsychiatric disturbances in Alzheimer's disease: what have we learned from neuropathological studies? Curr Alzheimer Res : () pdf(private)


2015 →top

Van der Mussele S, Le Bastard N, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S (2015) Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. Aging Ment Health 19(3): 247-57 () pdf(private)

Van der Mussele S, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2015) Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. Aging Ment Health 19(9): 818-28 () pdf(private)

Slaets S, Van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ, De Deyn PP, Engelborghs S (2015) Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry 30(8): 864-9 () pdf(private)

Kehoe K, Brouns R, Verkerk R, Engelborghs S, De Deyn PP, Hendriks D, De Meester I (2015) Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke. Neurochem Res 40(1): 81-8 () pdf(private)

Roth L, Van Dam D, Van der Donckt C, Schrijvers DM, Lemmens K, Van Brussel I, De Deyn PP, Martinet W, De Meyer GR (2015) Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. Physiol Behav : 397-402 () pdf(private)

Rosseels J, Van den Brande J, Violet M, Jacobs D, Grognet P, Lopez J, Huvent I, Caldara M, Swinnen E, Papegaey A, Caillierez R, Buée-Scherrer V, Engelborghs S, Lippens G, Colin M, Buée L, Galas MC, Vanmechelen E, Winderickx J (2015) Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. J Biol Chem 290(7): 4059-74 () pdf(private)

Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, Wagner U, Struyfs H, De Deyn PP, El-Moualij B, Zorzi W, Meyronet D, Streichenberger N, Engelborghs S, Kovacs GG, Quadrio I (2015) Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol 72(3): 267-75 () pdf(private)

Shah D, Blockx I, Guns PJ, De Deyn PP, Van Dam D, Jonckers E, Delgado Y Palacios R, Verhoye M, Van der Linden A (2015) Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. Neuroimage : 151-9 () pdf(private)

Niemantsverdriet E, Feyen BF, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, Engelborghs S (2015) Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. J Alzheimers Dis 45(4): 1039-43 () pdf(private)

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, Martin JJ, De Deyn PP (2015) The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther 7(1): 7 () pdf(private)

Braat S, D'Hulst C, Heulens I, De Rubeis S, Mientjes E, Nelson DL, Willemsen R, Bagni C, Van Dam D, De Deyn PP, Kooy RF (2015) The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle 14(18): 2985-95 () pdf(private)

Le Bastard N, De Deyn PP, Engelborghs S (2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 61(5): 734-43 () pdf(private)

Verreet T, Quintens R, Van Dam D, Verslegers M, Tanori M, Casciati A, Neefs M, Leysen L, Michaux A, Janssen A, D'Agostino E, Vande Velde G, Baatout S, Moons L, Pazzaglia S, Saran A, Himmelreich U, De Deyn PP, Benotmane MA (2015) A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. J Neurodev Disord 7(1): 3 () pdf(private)

Wostyn P, Van Dam D, Audenaert K, Killer HE, De Deyn PP, De Groot V (2015) A new glaucoma hypothesis: a role of glymphatic system dysfunction. Fluids Barriers CNS : 16 () pdf(private)

Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S (2015) Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Front Neurol : 138 () pdf(private)

Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ, (2015) Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 138(Pt 9): 2701-15 () pdf(private)

Dekker AD, Strydom A, Coppus AM, Nizetic D, Vermeiren Y, Naudé PJ, Van Dam D, Potier MC, Fortea J, De Deyn PP (2015) Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease? Cortex : 36-61 () pdf(private)

Amhaoul H, Hamaide J, Bertoglio D, Reichel SN, Verhaeghe J, Geerts E, Van Dam D, De Deyn PP, Kumar-Singh S, Katsifis A, Van Der Linden A, Staelens S, Dedeurwaerdere S (2015) Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiol Dis : 526-39 () pdf(private)


2014 →top

De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Mariën P, De Deyn PP, Engelborghs S (2014) Psychosocial problems associated with depression at 18 months poststroke. Int J Geriatr Psychiatry 29(2): 144-52 () pdf(private)

Van der Mussele S, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Behavioral syndromes in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 38(2): 319-29 () pdf(private)

Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, De Deyn PP, Engelborghs S (2014) Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement 10(5 Suppl): S290-8 () pdf(private)

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP (2014) Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. J Alzheimers Dis 41(3): 819-33 () pdf(private)

Struyfs H, Molinuevo JL, Martin JJ, De Deyn PP, Engelborghs S (2014) Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. J Alzheimers Dis 41(3): 903-9 () pdf(private)

De Ryck A, Brouns R, Geurden M, Elseviers M, De Deyn PP, Engelborghs S (2014) Risk factors for poststroke depression: identification of inconsistencies based on a systematic review. J Geriatr Psychiatry Neurol 27(3): 147-58 () pdf(private)

Van Dam D, Vermeiren Y, Aerts T, De Deyn PP (2014) Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. J Chromatogr A : 28-39 () pdf(private)

Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP (2014) Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiol Aging 35(12): 2691-700 () pdf(private)

Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mariën P, Saerens J, Somers N, Goeman J, De Deyn PP, Engelborghs S (2014) Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. J Alzheimers Dis 42(4): 1239-50 () pdf(private)

De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Mariën P, De Deyn PP, Engelborghs S (2014) Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. J Neurol Sci 347(1-2): 159-66 () pdf(private)


2013 →top

Van der Mussele S, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S (2013) Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. Int J Geriatr Psychiatry 28(3): 265-275 () pdf(private)

Azermai M, Petrovic M, Engelborghs S, Elseviers MM, Van der Mussele S, Debruyne H, Van Bortel L, Vander Stichele RH (2013) The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study. Aging Ment Health 17(1): 125-132 () pdf(private)

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J Alzheimers Dis 33(1): 117-131 () pdf(private)

Vermeiren Y, Le Bastard N, Van Hemelrijck A, Drinkenburg WH, Engelborghs S, De Deyn PP (2013) Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimers Dement 9(5): 488-498 () pdf(private)

Van der Mussele S, Bekelaar K, Le Bastard N, Vermeiren Y, Saerens J, Somers N, Mariën P, Goeman J, De Deyn PP, Engelborghs S (2013) Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease. Int J Geriatr Psychiatry 28(9): 947-958 () pdf(private)

De Deyn PP, Drenth AF, Kremer BP, Oude Voshaar RC, Van Dam D (2013) Aripiprazole in the treatment of Alzheimer's disease. Expert Opin Pharmacother 14(4): 459-474 () pdf(private)

Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, Teunissen C, Engelborghs S (2013) Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 59(4): 710-712 () pdf(private)

Wostyn P, De Groot V, Van Dam D, Audenaert K, De Deyn PP (2013) Senescent changes in cerebrospinal fluid circulatory physiology and their role in the pathogenesis of normal-tension glaucoma. Am J Ophthalmol 156(1): 5-14.e2 () pdf(private)

Van Leuven W, Van Dam D, Moens L, De Deyn PP, Dewilde S (2013) A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. Biochim Biophys Acta 1834(9): 1764-1771 () pdf(private)

De Ryck A, Brouns R, Fransen E, Geurden M, Van Gestel G, Wilssens I, De Ceulaer L, Mariën P, De Deyn PP, Engelborghs S (2013) A prospective study on the prevalence and risk factors of poststroke depression. Cerebrovasc Dis Extra 3(1): 1-13 () pdf(private)

Van Dam D, Van Dijck A, Janssen L, De Deyn PP (2013) Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities. Curr Alzheimer Res 10(5): 449-468 () pdf(private)

Engelborghs S (2013) Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Rev Neurol (Paris) 169(10): 709-714 () pdf(private)

Wostyn P, De Groot V, Van Dam D, Audenaert K, De Deyn PP (2013) Intracranial pressure fluctuations: a potential risk factor for glaucoma? Acta Ophthalmol : () pdf(private)


2012 →top

Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8(1): 65-73 () pdf(private)

Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF (2012) Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 229(1): 244-249 () pdf(private)

Boon P, Engelborghs S, Hauman H, Jansen A, Lagae L, Legros B, Ossemann M, Sadzot B, Smets K, Urbain E, van Rijckevorsel K (2012) Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update. Acta Neurol Belg 112(2): 119-131 () pdf(private)

Engelborghs S, Le Bastard N (2012) The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther 16(3): 135-141 () pdf(private)

del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6(4): 419-430 () pdf(private)

Engelborghs S, Le Bastard N (2012) The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. J Neurol Sci 322(1-2): 197-199 () pdf(private)